Search Result

Pathways Recommended:	TGF-beta/Smad

Results for "

Beta catenin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TGF-beta/Smad (2) TGF-β Receptor (1) β-catenin (157) Akt (2) AMPK (2) Androgen Receptor (1) Antibiotic (13) Apoptosis (35) Autophagy (9) Bacterial (18) Bcl-2 Family (5) c-Myc (4) Carbonic Anhydrase (1) Casein Kinase (2) Caspase (1) CDK (9) CDKL (1) Ceramidase (1) COX (1) Cytochrome P450 (1) DNA Methyltransferase (1) DNA/RNA Synthesis (1) Drug Derivative (1) DYRK (1) E1/E2/E3 Enzyme (3) EGFR (1) Endogenous Metabolite (8) Epigenetic Reader Domain (1) ERK (4) Estrogen Receptor/ERR (1) Ferroptosis (3) Fluorescent Dye (1) Fungal (5) Glucocorticoid Receptor (2) GSK-3 (16) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (1) Histone Demethylase (2) HSP (2) Influenza Virus (1) Isotope-Labeled Compounds (3) JAK (2) JNK (4) Keap1-Nrf2 (2) Lipoxygenase (1) MDM-2/p53 (3) MEK (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (2) Mitophagy (1) MMP (2) Molecular Glues (3) Neuropeptide Y Receptor (1) NF-κB (6) NOD-like Receptor (NLR) (3) Nuclear Factor of activated T Cells (NFAT) (1) Organoid (5) Oxidative Phosphorylation (1) P-glycoprotein (1) p38 MAPK (4) Parasite (6) PARP (6) Phosphodiesterase (PDE) (3) PI3K (2) Porcupine (2) Potassium Channel (4) PPAR (2) PROTACs (4) Pyroptosis (3) Pyruvate Kinase (1) RANKL/RANK (4) RAR/RXR (1) Ras (1) Reactive Oxygen Species (9) SGK (2) STAT (2) Survivin (1) Tau Protein (1) Toll-like Receptor (TLR) (4) Wnt (130)
By Research Areas:	Cancer (185) Cardiovascular Disease (8) Endocrinology (5) Infection (17) Inflammation/Immunology (29) Metabolic Disease (28) Neurological Disease (25)

By Targets:

TGF-beta/Smad (2)

TGF-β Receptor (1)

β-catenin (157)

Akt (2)

AMPK (2)

Androgen Receptor (1)

Antibiotic (13)

Apoptosis (35)

Autophagy (9)

Bacterial (18)

Bcl-2 Family (5)

c-Myc (4)

Carbonic Anhydrase (1)

Casein Kinase (2)

Caspase (1)

CDK (9)

CDKL (1)

Ceramidase (1)

COX (1)

Cytochrome P450 (1)

DNA Methyltransferase (1)

DNA/RNA Synthesis (1)

Drug Derivative (1)

DYRK (1)

E1/E2/E3 Enzyme (3)

EGFR (1)

Endogenous Metabolite (8)

Epigenetic Reader Domain (1)

ERK (4)

Estrogen Receptor/ERR (1)

Ferroptosis (3)

Fluorescent Dye (1)

Fungal (5)

Glucocorticoid Receptor (2)

GSK-3 (16)

HDAC (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Acetyltransferase (1)

Histone Demethylase (2)

HSP (2)

Influenza Virus (1)

Isotope-Labeled Compounds (3)

JAK (2)

JNK (4)

Keap1-Nrf2 (2)

Lipoxygenase (1)

MDM-2/p53 (3)

MEK (1)

Microtubule/Tubulin (2)

Mitochondrial Metabolism (2)

Mitophagy (1)

MMP (2)

Molecular Glues (3)

Neuropeptide Y Receptor (1)

NF-κB (6)

NOD-like Receptor (NLR) (3)

Nuclear Factor of activated T Cells (NFAT) (1)

Organoid (5)

Oxidative Phosphorylation (1)

P-glycoprotein (1)

p38 MAPK (4)

Parasite (6)

PARP (6)

Phosphodiesterase (PDE) (3)

PI3K (2)

Porcupine (2)

Potassium Channel (4)

PPAR (2)

PROTACs (4)

Pyroptosis (3)

Pyruvate Kinase (1)

RANKL/RANK (4)

RAR/RXR (1)

Ras (1)

Reactive Oxygen Species (9)

SGK (2)

STAT (2)

Survivin (1)

Tau Protein (1)

Toll-like Receptor (TLR) (4)

Wnt (130)

By Research Areas:

Cancer (185)

Cardiovascular Disease (8)

Endocrinology (5)

Infection (17)

Inflammation/Immunology (29)

Metabolic Disease (28)

Neurological Disease (25)

240

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

*β-catenin-IN-3*	β-catenin Wnt CDK	Cancer
β-catenin-IN-3 (Compound C2) is a selective *β-catenin* inhibitor. β-catenin-IN-3 binds to allosteric site on the surface of β-catenin with K_D calculated at 54.96 nM. β-catenin-IN-3 selectively inhibits β-catenin via targeting a cryptic allosteric modulation site, lowers its cellular load. β-catenin-IN-3 significantly reduces viability of β-catenin driven cancer cells, and triggers β-catenin degradation via proteasome system in β-catenin-overexpressing cancer cells .

*β-catenin-IN-2* 2 Publications Verification	β-catenin	Cancer
β-catenin-IN-2 (Compound H1B1) is a potent *β-catenin* inhibitor. β-catenin-IN-2 can be used for the study of colorectal cancer .

*β-catenin-IN-6*	β-catenin	Cancer
β-catenin-IN-6 is a *β-catenin* inhibitor, targeting to canonical Wingless-related integration site signaling pathway. β-catenin-IN-6 inhibits human colorectal cancer cells proliferation, as well as in a β-catenin/RK3E mouse model .

*β-catenin-IN-4*	β-catenin	Cancer
β-catenin-IN-4 (Compound 39) is a *β-catenin* inhibitor with a K_i of 0.64 μM. β-catenin-IN-4 reduces the protein expression levels of cyclin D1 and c-Myc .

*β-catenin-IN-37*	β-catenin	Cancer
β-catenin-IN-37 is a selective *β-Catenin/T-cell factor protein-protein interaction* (β-catenin/Tcf PPI) inhibitor. β-catenin-IN-37 inhibits canonical Wnt signaling and the growth of colorectal cancer cells SW480 and HCT116 with the IC₅₀ values of 20 μM and 31 μM, respectively .

*β-catenin-IN-7*	Wnt	Cancer
β-catenin-IN-7 (Compound 9) is a *β-catenin* inhibitor. β-catenin-IN-7 inhibits the interaction between β-catenin and Tcf-4, and inhibits Wnt-dependent target gene expression. β-catenin-IN-7 has anti-cancer activity .

*β-catenin-IN-8*	β-catenin Wnt c-Myc	Cancer
β-catenin-IN-8 (Compound 25) is a *β-catenin* inhibitor. β-catenin-IN-8 inhibits β-catenin and c-Myc protein levels, and inhibits Wnt-target genes level (Fgf20 and Sall4). β-catenin-IN-8 has colorectal cancer anticancer activities, and has metabolic stability .

*β-Catenin* modulator-7**	β-catenin	Cancer
β-Catenin modulator-7 (Compound 5) is a modulator for *β-catenin. β-Catenin* modulator-7 inhibits the expression of β-catenin in HCT-116 cytoplasm and nucleus, suppresses the phosphorylation of GSK 3β. β-Catenin modulator-7 promotes NO release in HCT-116, and inhibits the proliferation of cancer cell HCT-116 with IC₅₀ of 0.6-0.9 μM. β-Catenin modulator-7 can be used in reasearch about colon cancer .

*Wnt/β-catenin-IN-4*	Wnt	Metabolic Disease
Wnt/β-catenin-IN-4 (compound YW1159) is a potent *Wnt/β-catenin* inhibitor .

*β-catenin* modulator IIa-661**	β-catenin Wnt	Cancer
β-catenin modulator IIa-661 is a *β-catenin* modulator that modulates β-catenin activity and inhibits the activity of the Wnt/wingless (wg) signaling pathway. β-catenin modulator IIa-661 can be utilized in cancer research .

*Wnt/β-catenin-IN-2*	Wnt β-catenin	Cancer
Wnt/β-catenin-IN-2 (Compound 3235-0367) is a *Wnt/β-catenin* signaling pathway inhibitor, with IC₅₀ and K_D values of 7.1 and 2.5 μM, respectively. Wnt/β-catenin-IN-2 can be used for the research of cancer .

*β-Catenin* modulator-8**	β-catenin	Cancer
β-Catenin modulator-8 (Compound Ⅸa) is a *β-Catenin* modulator and can be used for cancer research .

*β-Catenin* modulator-1**	β-catenin	Cancer
β-Catenin modulator-1 (IIa-650) is a β-Catenin modulator useful in cancer research .

*Wnt/β-catenin-IN-1*	Wnt β-catenin	Cancer
Wnt/β-catenin-in-1 (compounds 17) is a *Wnt/β-catenin* signaling pathway inhibitor. Wnt/β-catenin-IN-1 can induce apoptosis of colon cancer cells, has broad-spectrum anticancer activity, and can be used for the reseach of a variety of solid tumors .

*β-Catenin* modulator-5**	β-catenin	Cancer
β-Catenin modulator-5 (compound IIa-84), an oxazole and thiazole compound, is a potent and selective β-Catenin modulator .

*β-Catenin* modulator-3**	β-catenin	Cancer
β-Catenin modulator-3 (compound IIa-112), an oxazole and thiazole compound, is a potent and selective β-Catenin modulator .

*β-Catenin* modulator-4**	β-catenin	Cancer
β-Catenin modulator-4 (compound IIa-92), an oxazole and thiazole compound, is a potent and selective β-Catenin modulator .

*β-Catenin* modulator-2**	β-catenin	Cancer
β-Catenin modulator-2 (compound IIa-130), an oxazole and thiazole compound, is a potent and selective β-Catenin modulator .

*Wnt/β-catenin* agonist 3**	β-catenin	Cardiovascular Disease
Wnt/β-catenin agonist 3 (compound 98) is a *Wnt/β-catenin* signalling pathway agonist. Wnt/β-catenin agonist 3 can be used for the research of osteoporosis .

*Wnt/β-catenin* agonist 3 hydrochloride**	β-catenin	Others
Wnt/β-catenin agonist 3 hydrochloride is a *Wnt/β-catenin* signalling pathway agonist. Wnt/β-catenin agonist 3 (compound 98) can be used for the research of osteoporosis .

*PTK7/β-catenin-IN-2*	β-catenin	Cancer
PTK7/β-catenin-IN-2 (compound 04967) is an inhibitor of *PTK7/β-catenin*. It inhibits the binding of PTK7 to β-catenin (IC₅₀: 5.6 μM), thereby inhibiting the signaling of the Wnt/β-catenin pathway. PTK7/β-catenin-IN-2 targets cell growth dependent on the Wnt signaling pathway and has anticancer properties. PTK7/β-catenin-IN-2 also showed inhibitory potency against p53 and MDM2 binding with an IC₅₀ of 157.1 μM .

*hCA/Wnt/β-catenin-IN-1*	Carbonic Anhydrase P-glycoprotein Wnt β-catenin	Cancer
hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (K_i: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits *Wnt/β-catenin* signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .

*PTK7/β-catenin-IN-1*	β-catenin	Cancer
PTK7/β-catenin-IN-1 (compound 01065) is a potent *PTK7/β-catenin* inhibitor with an IC₅₀ of 8.9 μM and 56.5 μM for PTK7/β-catenin and p53/MDM2, respectively. PTK7/β-catenin-IN-1 has the potential for cancer research .

*Wnt/β-catenin* agonist 4**	Wnt	Cancer
Wnt/β-catenin agonist 4 (Derivative 83) is an agonist of Wnt that activates *Wnt/β-catenin* signal transmission .

*Wnt/β-catenin* agonist 2**	β-catenin	Others
Wnt/β-catenin agonist 2 is a potent Wnt agonist. Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and can be used in the research of diseases related to the signal transduction . (From patent WO2007078113A1, compound 39)

*Wnt/β-catenin-IN-3*	Wnt β-catenin MDM-2/p53	Cancer
Wnt/β-catenin-IN-3 (compound 17) is a *Wnt/β-catenin* inhibitor with low micromolarGI₅₀s against various cancer cells. Wnt/β-catenin-IN-3triggers G2/M cell cycle arrest though activation of p53-p21 pathway as well as intrinsic and extrinsic apoptotic death of colon cancer cells .

*Wnt/β-catenin* agonist 1** 4 Publications Verification	Wnt	Cancer
Wnt/β-catenin agonist 1 (compound 3f) is a *Wnt/β-catenin* signalling pathway agonist, with an EC₅₀ of 0.27 μM .

*β-catenin* peptide**	β-catenin	Cancer
β-catenin peptide is a 8-aa peptide, and can promote thymocyte positive selection.

*β-catenin/BCL9 PPI-IN-1*	β-catenin	Cancer
β-catenin/BCL9 PPI-IN-1 (compound B4) is a potent inhibitor of β catenin/B-Cell lymphoma 9 protein?protein interaction (β catenin/BCL9 PPI) with the IC₅₀ value of 2.25 μM .

*PTK7/β-catenin-IN-6*	Wnt β-catenin	Cancer
PTK7/β-catenin-IN-6 (Compound 03653) is an inhibitor for PTK7/β-catenin interaction, which inhibits the Wnt signaling pathway, and exhibits an anticancer activity against colorectal cancer (CRC) .

*TCF4/β-catenin-IN-1*	β-catenin Apoptosis Caspase MDM-2/p53 Bcl-2 Family Cytochrome P450	Cancer
TCF4/β-catenin-IN-1 (Compound 8b) is an inhibitor of *TCF4/β-catenin*, and induces apoptosis. TCF4/β-catenin-IN-1 up-regulates p53, caspase-3, caspase-8, caspase-9 levels and Bax protein expression as well as down-regulates Bcl-2 protein expression. TCF4/β-catenin-IN-1 can inhibit CYP3A4, CYP1A2, CYP2C19, and shows promising cytotoxic activity in cancer cells .

*Wnt/β-catenin* activator 1**	Wnt β-catenin	Metabolic Disease
Wnt/β-catenin activator 1 (Compound 5m) is the orally active activator for *Wnt/β-catenin* signaling pathway, that arrests cell cycle at G1 phase, inhibits early proliferation of adipocytes, and inhibits adipogenesis in cell 3T3-L1 with an IC₅₀ of 330 nM. Wnt/β-catenin activator 1 exhibits anti-adipogenic and anti-dyslipidemic activities in high-fat diet fed Syrian golden hamster model .

SKL2001 45+ Cited Publications	Wnt β-catenin	Cancer
SKL2001 is an agonist of the *Wnt/β-catenin* pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction .

Windorphen	Wnt β-catenin Histone Acetyltransferase	Cancer
Windorphen is a *Wnt/β-catenin* signal inhibitor that specifically targets the function of the c-terminal transactivation domain of *β-catenin-1* but not β-catenin-2. Windorphen selectively targets p300, disrupting the association of the mammalian β-catenin with p300 but not CBP .

C-82	β-catenin Wnt	Cancer
C-82 is a second-generation specific *CBP/β-catenin* antagonist, which inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300 .

Tegatrabetan 1 Publications Verification Tegavivint; BC2059	β-catenin	Cancer
Tegatrabetan (BC2059) is a *β-Catenin* antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) .

xStAx-VHLL	Wnt PROTACs β-catenin	Cancer
xStAx-VHLL is a *β-catenin* PROTAC degrader that promotes ubiquitination and proteasome degradation of β-catenin. xStAx-VHLL inhibits the Wnt/β-catenin** signaling pathway. xStAx-VHLL can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

MSAB 25+ Cited Publications	Wnt β-catenin	Cancer
MSAB is a potent and selective inhibitor of *Wnt/β-catenin* signaling. MSAB binds to β-catenin and promotes its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells .

SKL2001 (GMP)	Wnt β-catenin	Cancer
SKL2001 (GMP) is SKL2001 (HY-101085) produced by using GMP guidelines. SKL2001 is an agonist of the *Wnt/β-catenin* pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction .

iCRT-5	β-catenin	Cancer
iCRT-5 is a *β-catenin-regulated transcription (CRT)* inhibitor. iCRT-5 can block *Wnt/β-catenin* reporter activity and down regulate β-catenin expression. iCRT-5 can be used for the research of multiple myeloma .

xStAx-VHLL TFA	PROTACs β-catenin Wnt	Cancer
xStAx-VHLL TFA is a *β-catenin* PROTAC degrader that promotes ubiquitination and proteasome degradation of β-catenin. xStAx-VHLL TFA inhibits the Wnt/β-catenin** signaling pathway. xStAx-VHLL TFA can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

UU-T01	β-catenin	Cancer
UU-T01 is a selective inhibitor for *β-Catenin/T-cell factor 4 protein-protein interaction* (β-catenin/Tcf PPI) with an K_i value of 3.14 µM. UU-T01 is directly combined with β-catenin, and the K_D value is 0.531 µM .

ZW4864	β-catenin	Cancer
ZW4864 is an orally active and selective β catenin/B-Cell lymphoma 9 protein protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 inhibits *β catenin/BCL9 PPI* with a K_i value of 0.76 μM and an IC₅₀ value of 0.87 μM .

KY1220 3 Publications Verification	Wnt β-catenin	Cancer
KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the *Wnt/β-catenin* pathway; with an IC₅₀ of 2.1 μM in HEK293 reporter cells.

NRX-252262	Molecular Glues β-catenin E1/E2/E3 Enzyme	Cancer
NRX-252262 is a potent enhancer of the interaction between *β-Catenin, and its cognate E3 ligase, SCF ^β-TrCP, induces mutant β-catenin* degradation, with an EC₅₀ of 3.8 nM .

ZW4864 free base	β-catenin	Cancer
ZW4864 (free base) is an orally active and selective β catenin/B-Cell lymphoma 9 protein protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 (free base) inhibits *β catenin/BCL9 PPI* with a K_i value of 0.76 μM and an IC₅₀ value of 0.87 μM .

Cat. No.	Product Name

HY-L201

Cell Proliferation Compound Library

2,548 compounds

Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others.

MCE collects 2,548 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.

HY-L038

Differentiation Inducing Compound Library

1,799 compounds

Stem cells, which are found in all multi-cellular organisms, can divide and differentiate into diverse special cell types and can self-renew to produce more stem cells. To be useful in therapy, stem cells must be converted into desired cell types as necessary which is called induced differentiation or directed differentiation. Understanding and using signaling pathways for differentiation is an important method in successful regenerative medicine. Small molecules or growth factors induce the conversion of stem cells into appropriate progenitor cells, which will later give rise to the desired cell type. There is a variety of signal molecules and molecular families that may affect the establishment of germ layers in vivo, such as fibroblast growth factors (FGFs); the wnt family or superfamily of transforming growth factors β (TGFβ) and bone morphogenetic proteins (BMP). Unfortunately, for now, a high cost of recombinant factors is likely to limit their use on a larger scale in medicine. The more promising technique focuses on the use of small molecules. These small molecules can be used for either activating or deactivating specific signaling pathways. They enhance reprogramming efficiency by creating cells that are compatible with the desired type of tissue. It is a cheaper and non-immunogenic method.

MCE Differentiation Inducing Compound Library contains a unique collection of 1,799 compounds that act on signaling pathways for differentiation. These compounds are potential stimulators for induced differentiation. This library is a useful tool for researching directed differentiation and regenerative medicine.

HY-L020

Wnt/Hedgehog/Notch Compound Library

445 compounds

The developmental proteins Hedgehog, Notch and Wnt are key regulators of cell fate, proliferation, migration and differentiation in several tissues. Their related signaling pathways are frequently activated in tumors, and particularly in the rare subpopulation of cancer stem cells. The Wnt signaling pathway is a conserved pathway in animals. Deregulated Wnt signaling has catastrophic consequences for the developing embryo and it is now well appreciated that defective Wnt signaling is a causative factor for a number of pleiotropic human pathologies, including cancer. Hedgehog signaling pathway is linked to tumorigenesis and is aberrantly activated in a variety of cancers. The Notch signaling pathway is a highly conserved cell signaling system present in most animals. It plays an important role in cell-cell communication, and further regulates embryonic development.

MCE designs a unique collection of 445 Wnt/Hedgehog/Notch signaling pathway-related small molecules. Wnt/Hedgehog/Notch Compound Library serves as a useful tool for stem cell research and anti-cancer drug screening.

HY-L103

Anti-Colorectal Cancer Compound Library

1,932 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,932 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-101085G

SKL2001 (GMP)	Fluorescent Dye
SKL2001 (GMP) is SKL2001 (HY-101085) produced by using GMP guidelines. SKL2001 is an agonist of the *Wnt/β-catenin* pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction .

Cat. No.	Product Name	Type

HY-101085G

SKL2001 (GMP)	Biochemical Assay Reagents
SKL2001 (GMP) is SKL2001 (HY-101085) produced by using GMP guidelines. SKL2001 is an agonist of the *Wnt/β-catenin* pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction .

Cat. No.	Product Name	Target	Research Area

HY-P5819

xStAx-VHLL	Wnt PROTACs β-catenin	Cancer
xStAx-VHLL is a *β-catenin* PROTAC degrader that promotes ubiquitination and proteasome degradation of β-catenin. xStAx-VHLL inhibits the Wnt/β-catenin** signaling pathway. xStAx-VHLL can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

HY-P5819A

xStAx-VHLL TFA	PROTACs β-catenin Wnt	Cancer
xStAx-VHLL TFA is a *β-catenin* PROTAC degrader that promotes ubiquitination and proteasome degradation of β-catenin. xStAx-VHLL TFA inhibits the Wnt/β-catenin** signaling pathway. xStAx-VHLL TFA can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

HY-P4858

C-Peptide 1 (rat)	GSK-3	Cancer
C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer .

HY-P10392AF

fStAx-35R TFA	β-catenin	Cancer
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits *Wnt/β-catenin* signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .

HY-P10392B

aStAx-35R TFA	β-catenin Wnt	Cancer
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of *β-catenin* and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-P1589

*β-catenin* peptide**	β-catenin	Cancer
β-catenin peptide is a 8-aa peptide, and can promote thymocyte positive selection.

HY-P10925

I-66	β-catenin	Cancer
I-66 is a potent *β-catenin* inhibitor with an IC₅₀ of <50 nM. I-66 can inhibits β-catenin and T-cell factor (TCF) transcription factor interaction. I-66 shows anticancer effects .

HY-P10925A

I-67	β-catenin	Cancer
I-67, a structural isomer of I-66 (HY-P10925), is a potent *β-catenin* inhibitor with an IC₅₀ of <50 nM. I-67 can inhibits β-catenin and T-cell factor (TCF) transcription factor interaction. I-67 shows anticancer effects .

HY-P10392

aStAx-35R	β-catenin Wnt	Cancer
aStAx-35R, a stapled peptide, antagonizes nuclear form of *β-catenin* and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-107528

FRATtide	β-catenin GSK-3	Cancer
FRATtide is a peptide derived from the GSK-3 binding protein that inhibits the phosphorylation of Axin and *β-catenin. FRATtide inhibits GSK-3* binding to Axin .

HY-P6441

KP-6	β-catenin Wnt	Inflammation/Immunology
KP-6, a polypeptide, is a *Wnt/β-catenin* signal inhibitor. KP-6 inhibits TGF-β and blocks rush fibrosis signal path crucial in vivo. KP-6 suppresses Renal tissues damage and renal fibrosis, and reverse the course of disease of chronic kidney disease (CKD) .

HY-P2272

NLS-StAx-h	Wnt β-catenin	Cancer
NLS-StAx-h is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC₅₀ of 1.4 μM. NLS-StAx-h efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h shows anti-proliferation of cancer cells .

HY-P2272A

NLS-StAx-h TFA 1 Publications Verification	Wnt β-catenin	Cancer
NLS-StAx-h TFA is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC₅₀ of 1.4 μM. NLS-StAx-h TFA efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h TFA shows anti-proliferation of cancer cells .

HY-P10652

hsBCL9CT-24	Wnt β-catenin	Cancer
hsBCL9CT-24 is a *Wnt/β-catenin* (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research .

HY-P1416

Foxy-5 Maximum Cited Publications 6 Publications Verification	Wnt	Cancer
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P10810

QPH-FR	Wnt β-catenin	Cancer
QPH-FR, a quinoa peptide, is a leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) inhibitor. QPH-FR competitively suppresses the formation of the LGR5/RSPO1 complex by binding to LGR5. QPH-FR causes RNF43/ZNRF3 to ubiquitinate the FZD receptor, thereby suppressing the *Wnt/β-catenin* signaling pathway and exerting stemness inhibition .

HY-P1454

Fz7-21 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .

HY-P1454A

Fz7-21 TFA 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2 TFA	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .

HY-P1416A

Foxy-5 TFA Maximum Cited Publications 6 Publications Verification	Wnt	Cancer
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

Species:	Human (1) Mouse (1)
Tag:	His (2) GST (2)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P74381

	beta-Catenin Protein, Mouse (sf9, His-GST) Beta-catenin; catenin Beta-1; CTNNB; CTNNB1	Mouse	Sf9 insect cells
	β-Catenin is a key component of canonical Wnt signaling, which dynamically controls cellular processes. In the absence of Wnt, it forms a complex leading to phosphorylation and degradation. beta-Catenin Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived beta-Catenin protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of beta-Catenin Protein, Mouse (sf9, His-GST) is 781 a.a., with molecular weight of ~115 kDa.

HY-P74382

	beta-Catenin Protein, Human (sf9, His-GST) Beta-catenin; catenin Beta-1; CTNNB; CTNNB1	Human	Sf9 insect cells
	Beta-Catenin protein is an important component of the canonical Wnt pathway and regulates cellular processes. In the absence of Wnt, it complexes with AXIN1, AXIN2, APC, CSNK1A1, and GSK3B to promote CTNNB1 phosphorylation and degradation. beta-Catenin Protein, Human (sf9, His-GST) is the recombinant human-derived beta-Catenin protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of beta-Catenin Protein, Human (sf9, His-GST) is 781 a.a., with molecular weight of ~116 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-N0060BS

(E)-Ferulic acid-d3

(E)-Ferulic acid-d₃ is the deuterium labeled (E)-Ferulic acid. (E)-Ferulic acid is a isomer of Ferulic acid which is an aromatic compound, abundant in plant cell walls. (E)-Ferulic acid causes the phosphorylation of β-catenin, resulting in proteasomal degradation of β-catenin and increases the expression of pro-apoptotic factor Bax and decreases the expression of pro-survival factor survivin. (E)-Ferulic acid shows a potent ability to remove reactive oxygen species (ROS) and inhibits lipid peroxidation. (E)-Ferulic acid exerts both anti-proliferation and anti-migration effects in the human lung cancer cell line H1299[1].

HY-B1057S

Nefopam-d3 hydrochloride
Nefopam-d₃ (hydrochloride) is the deuterium labeled Nefopam hydrochloride. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].

HY-B1057S2

Nefopam-d3
Nefopam-d₃ is a deuterium labeled Nefopam (Fenazoxine). Nefopam is a centrally-acting but non-opioid analgesic drug, and Nefopam targets β-catenin protein level in mesenchymal cells[1][2].

HY-N8015S2

Octanal-d4
Octanal-d₄ is deuterated labeled Methyl vanillate (HY-75342). Methyl vanillate, one of the ingredients in Oryza sativa Linn., is a *Wnt/β-catenin* pathway activator . A benzoate ester that is the methyl ester of vanillic acid. It has a role as an antioxidant and a plant metabolite.

HY-100760S

Toxoflavin-13C4
Toxoflavin- ¹³C₄ is the ¹³C-labeled Toxoflavin. Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor activity[1][2]. Antibiotic properties.

HY-B1057S1

Nefopam-d4 hydrochloride
Nefopam-d₄ (hydrochloride) is deuterium labeled Nefopam (hydrochloride). Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81261

	beta Catenin Antibody (YA936) CTNNB1; CTNNB; OK/SW-cl.35; catenin Beta-1; Beta-catenin	WB, IHC-P	Human, Mouse, Rat
	beta Catenin Antibody (YA936) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA936), targeting beta Catenin, with a predicted molecular weight of 85 kDa (observed band size: 92 kDa). beta Catenin Antibody (YA936) can be used for WB, IHC-P experiment in human, mouse, rat background.

HY-P81261B

	beta Catenin Antibody (YA938) CTNNB1; CTNNB; OK/SW-cl.35; catenin Beta-1; Beta-catenin	WB, IHC-P, IP	Human, Mouse, Rat, Hamster
	beta Catenin Antibody (YA938) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA938), targeting beta Catenin, with a predicted molecular weight of 85 kDa (observed band size: 85 kDa). beta Catenin Antibody (YA938) can be used for WB, IHC-P, IP experiment in human, mouse, rat, hamster background.

HY-P80488

	Beta-Catenin Antibody	WB, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	Beta-Catenin Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 85 kDa, targeting to Beta-Catenin. It can be used for WB,IHC-P,IF,IP assays with tag free, in the background of Human, Mouse,Rat.

HY-P83351

	*Phospho-beta* Catenin (Ser33/Ser37) Antibody (YA3096)** CTNNB1; CTNNB; OK/SW-cl.35; catenin Beta-1; Beta-catenin	WB	Human, Rat
	Phospho-beta Catenin (Ser33/Ser37) Antibody (YA3096) is a non-conjugated IgG antibody, targeting Phospho-beta Catenin (Ser33/Ser37), with a predicted molecular weight of 85 kDa (observed band size: 92 kDa). Phospho-beta Catenin (Ser33/Ser37) Antibody (YA3096) can be used for WB experiment in human, rat background.

HY-P81261A

	beta Catenin Antibody (YA937) CTNNB1; CTNNB; OK/SW-cl.35; catenin Beta-1; Beta-catenin	WB	Human, Mouse, Rat
	beta Catenin Antibody (YA937) is a non-conjugated IgG1 antibody, targeting beta Catenin, with a predicted molecular weight of 85 kDa (observed band size: 92 kDa). beta Catenin Antibody (YA937) can be used for WB experiment in human, mouse, rat background.